Hikari Power Ltd maintained its position in Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 57,400 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Celgene Corporation comprises 1.0% of Hikari Power Ltd’s investment portfolio, making the stock its 24th biggest position. Hikari Power Ltd’s holdings in Celgene Corporation were worth $7,455,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Celgene Corporation in the 1st quarter valued at $118,000. Motco grew its stake in Celgene Corporation by 19.3% in the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 159 shares during the period. Acropolis Investment Management LLC acquired a new stake in Celgene Corporation in the 2nd quarter valued at $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in Celgene Corporation by 47.5% in the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 380 shares during the period. Finally, Rational Advisors LLC acquired a new stake in Celgene Corporation in the 2nd quarter valued at $156,000. 78.92% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2017/11/06/hikari-power-ltd-maintains-holdings-in-celgene-corporation-celg.html.
CELG has been the topic of a number of research analyst reports. Vetr cut shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 price target on the stock. in a research note on Tuesday, August 29th. Royal Bank Of Canada decreased their price objective on Celgene Corporation from $166.00 to $148.00 and set a “top pick” rating on the stock in a report on Friday, October 27th. Leerink Swann restated a “buy” rating and issued a $156.00 price objective on shares of Celgene Corporation in a report on Friday, October 20th. Morgan Stanley decreased their price objective on Celgene Corporation from $120.00 to $115.00 and set an “underweight” rating on the stock in a report on Monday, October 23rd. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Celgene Corporation in a report on Monday, August 28th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company. Celgene Corporation has a consensus rating of “Buy” and an average target price of $139.64.
Celgene Corporation (NASDAQ CELG) opened at $100.04 on Monday. Celgene Corporation has a fifty-two week low of $94.55 and a fifty-two week high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $78,763.19, a price-to-earnings ratio of 15.63, a PEG ratio of 0.77 and a beta of 1.79.
Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. Celgene Corporation’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.58 EPS. research analysts expect that Celgene Corporation will post 6.67 earnings per share for the current year.
In related news, Director Ernest Mario sold 18,506 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the sale, the director now directly owns 69,424 shares in the company, valued at approximately $9,061,220.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares in the company, valued at $564,768.25. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,733 shares of company stock worth $5,259,359. 0.95% of the stock is owned by insiders.
Celgene Corporation Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.